KR101728375B1 - 시토크롬 ｐ４５０ 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 - Google Patents
시토크롬 ｐ４５０ 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 Download PDFInfo
- Publication number
- KR101728375B1 KR101728375B1 KR1020117026120A KR20117026120A KR101728375B1 KR 101728375 B1 KR101728375 B1 KR 101728375B1 KR 1020117026120 A KR1020117026120 A KR 1020117026120A KR 20117026120 A KR20117026120 A KR 20117026120A KR 101728375 B1 KR101728375 B1 KR 101728375B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- delete delete
- compound
- salt
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *N[C@@](Cc1ccccc1)CO* Chemical compound *N[C@@](Cc1ccccc1)CO* 0.000 description 5
- QEYXFSIVDPCIQM-AWEZNQCLSA-N CC(C)c1nc(CN(C)C(N[C@@H](CCN2CCOCC2)C(O)=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@@H](CCN2CCOCC2)C(O)=O)=O)c[s]1 QEYXFSIVDPCIQM-AWEZNQCLSA-N 0.000 description 1
- CCSVVYNNTWRTHI-JTQLQIEISA-N CC(C)c1nc(CN(C)C(N[C@@H](CCO2)C2=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@@H](CCO2)C2=O)=O)c[s]1 CCSVVYNNTWRTHI-JTQLQIEISA-N 0.000 description 1
- HWSFABGWAXURNG-UHFFFAOYSA-N CC(C)c1nc(CNC)c[s]1 Chemical compound CC(C)c1nc(CNC)c[s]1 HWSFABGWAXURNG-UHFFFAOYSA-N 0.000 description 1
- VUQXPFUEFMHJPV-INIZCTEOSA-N CCOC([C@H](CCN1CCOCC1)NC(N(C)Cc1c[s]c(C(C)C)n1)=O)=O Chemical compound CCOC([C@H](CCN1CCOCC1)NC(N(C)Cc1c[s]c(C(C)C)n1)=O)=O VUQXPFUEFMHJPV-INIZCTEOSA-N 0.000 description 1
- XEHVTXPRUGMXGR-FGZHOGPDSA-N Cc1ncc(COC(N[C@H](CC[C@H](Cc2ccccc2)N)Cc2ccccc2)=O)[s]1 Chemical compound Cc1ncc(COC(N[C@H](CC[C@H](Cc2ccccc2)N)Cc2ccccc2)=O)[s]1 XEHVTXPRUGMXGR-FGZHOGPDSA-N 0.000 description 1
- CTVQBUFULGSGGL-QZTJIDSGSA-N N[C@H](CC[C@H](Cc1ccccc1)N)Cc1ccccc1 Chemical compound N[C@H](CC[C@H](Cc1ccccc1)N)Cc1ccccc1 CTVQBUFULGSGGL-QZTJIDSGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
- C07C209/70—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by reduction of unsaturated amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/34—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfuric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16649809P | 2009-04-03 | 2009-04-03 | |
| US61/166,498 | 2009-04-03 | ||
| PCT/US2010/029633 WO2010115000A2 (en) | 2009-04-03 | 2010-04-01 | Methods and intermediates for preparing pharmaceutical agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177009970A Division KR101874557B1 (ko) | 2009-04-03 | 2010-04-01 | 시토크롬 ｐ４５０ 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120006035A KR20120006035A (ko) | 2012-01-17 |
| KR101728375B1 true KR101728375B1 (ko) | 2017-04-19 |
Family
ID=42634770
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117026120A Active KR101728375B1 (ko) | 2009-04-03 | 2010-04-01 | 시토크롬 ｐ４５０ 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 |
| KR1020177009970A Active KR101874557B1 (ko) | 2009-04-03 | 2010-04-01 | 시토크롬 ｐ４５０ 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 |
| KR1020187018487A Ceased KR20180077324A (ko) | 2009-04-03 | 2010-04-01 | 시토크롬 ｐ４５０ 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177009970A Active KR101874557B1 (ko) | 2009-04-03 | 2010-04-01 | 시토크롬 ｐ４５０ 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 |
| KR1020187018487A Ceased KR20180077324A (ko) | 2009-04-03 | 2010-04-01 | 시토크롬 ｐ４５０ 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8497396B2 (OSRAM) |
| EP (2) | EP3009434A1 (OSRAM) |
| JP (8) | JP5612662B2 (OSRAM) |
| KR (3) | KR101728375B1 (OSRAM) |
| CN (4) | CN111217808A (OSRAM) |
| AP (1) | AP2887A (OSRAM) |
| AR (1) | AR076027A1 (OSRAM) |
| AU (1) | AU2010232559B2 (OSRAM) |
| BR (1) | BRPI1012638B8 (OSRAM) |
| CA (4) | CA3008903C (OSRAM) |
| CL (1) | CL2011002370A1 (OSRAM) |
| CO (1) | CO6400216A2 (OSRAM) |
| EA (2) | EA201590979A1 (OSRAM) |
| EC (1) | ECSP11011391A (OSRAM) |
| ES (1) | ES2548252T3 (OSRAM) |
| HK (1) | HK1223912A1 (OSRAM) |
| IL (4) | IL215399A (OSRAM) |
| MX (2) | MX2011010397A (OSRAM) |
| NZ (4) | NZ617773A (OSRAM) |
| PE (1) | PE20120617A1 (OSRAM) |
| PT (1) | PT2414325E (OSRAM) |
| SG (2) | SG10201404926UA (OSRAM) |
| TW (2) | TW201518283A (OSRAM) |
| UA (1) | UA108738C2 (OSRAM) |
| UY (1) | UY32535A (OSRAM) |
| WO (1) | WO2010115000A2 (OSRAM) |
| ZA (1) | ZA201107430B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108738C2 (uk) | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
| JP2012140390A (ja) * | 2011-01-06 | 2012-07-26 | Sumitomo Chemical Co Ltd | α−アミノ−γ−ブチロラクトンの製造方法 |
| CA2836768A1 (en) * | 2011-05-02 | 2012-11-08 | Gilead Sciences, Inc. | Amorphous solid salts |
| SG11201404527QA (en) * | 2012-02-03 | 2014-08-28 | Gilead Sciences Inc | Methods and intermediates for preparing pharmaceutical agents |
| WO2014047849A1 (zh) * | 2012-09-27 | 2014-04-03 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
| CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
| WO2014057498A2 (en) | 2012-10-08 | 2014-04-17 | Mylan Laboratories Ltd. | Process for the preparation of cobicistat intermediates |
| WO2014105777A1 (en) * | 2012-12-26 | 2014-07-03 | Assia Chemical Industries Ltd. | Cobicostat dichlohydrate salt |
| CN104370777A (zh) * | 2013-08-13 | 2015-02-25 | 上海迪赛诺化学制药有限公司 | 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用 |
| US20170035911A1 (en) * | 2013-11-29 | 2017-02-09 | Mylan Laboratories Ltd. | Amorphous Cobicistat Solid Dispersion |
| EP3077373B1 (en) | 2013-12-03 | 2018-09-12 | Mylan Laboratories Ltd. | Preparation of cobicistat intermediates |
| CN104193643B (zh) * | 2014-09-12 | 2016-02-10 | 宁波九胜创新医药科技有限公司 | 用于合成抗艾滋病药物增强剂cobicistat的中间体 |
| CN104447472A (zh) * | 2014-11-06 | 2015-03-25 | 江苏森萱医药化工股份有限公司 | D)-2-苄基-n,n-二甲基氮杂环丙烷基-1-磺酰胺合成方法 |
| CN104557565B (zh) * | 2015-01-08 | 2016-07-06 | 浙江工业大学 | 抗艾滋病药物增强剂Cobicistat关键中间体盐酸盐的制备方法 |
| US10454867B2 (en) * | 2015-02-09 | 2019-10-22 | Airwatch Llc | Enhanced e-mail delivery to mobile devices |
| WO2016132378A2 (en) * | 2015-02-18 | 2016-08-25 | Msn Laboratories Private Limited | Novel process for the preparation of 1,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2- [(methyl{[2-(propan-2-yl)- 1,3-thiazol-4-yl] methyl} carbamoyl) amino] -4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl] carbamate |
| CN107674039A (zh) * | 2016-08-01 | 2018-02-09 | 上海朴颐化学科技有限公司 | 一种可比西他中间体的制备方法 |
| US20180085387A1 (en) | 2016-09-27 | 2018-03-29 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| CN109912530A (zh) * | 2017-12-13 | 2019-06-21 | 上海奥博生物医药技术有限公司 | 一种可比司他原料杂质的制备方法 |
| CN109232301B (zh) * | 2018-10-15 | 2021-01-01 | 天津希恩思生化科技有限公司 | 一种四异丙基肼的制备方法 |
| CN110642721B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 盐酸司来吉兰的制备方法 |
| CN110878071A (zh) * | 2019-11-21 | 2020-03-13 | 华南农业大学 | 一种α-氨基-γ-丁内酯及其盐的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008103949A1 (en) * | 2007-02-23 | 2008-08-28 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2324549T5 (es) * | 1999-06-04 | 2012-10-31 | Abbott Laboratories | Solución farmacéutica que comprende ritonavir, un disolvente (ácido graso de cadena larga) y agua |
| US20030153771A1 (en) | 2001-09-27 | 2003-08-14 | Kolb Hartmuth C. | Large scale synthesis of optically pure aziridines |
| WO2003106445A1 (en) * | 2002-06-12 | 2003-12-24 | Qsi Pharma A/S | Compounds and methods for controlling bacterial virulence |
| JP2008507611A (ja) * | 2004-07-23 | 2008-03-13 | ザ プロクター アンド ギャンブル カンパニー | 油及びデンプン汚れに対する低温での洗浄力を向上させる液体洗剤組成物 |
| US7786153B2 (en) * | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
| AP2985A (en) * | 2006-07-07 | 2014-09-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| CA2692331A1 (en) * | 2007-07-06 | 2009-01-15 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| ES2555209T3 (es) * | 2008-01-04 | 2015-12-29 | Gilead Sciences, Inc. | Inhibidores del citocromo P450 |
| BRPI0911871A8 (pt) | 2008-05-02 | 2018-03-06 | Gilead Sciences Inc | uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico |
| UA108738C2 (uk) | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки |
-
2010
- 2010-01-04 UA UAA201111540A patent/UA108738C2/ru unknown
- 2010-03-31 AR ARP100101077 patent/AR076027A1/es unknown
- 2010-03-31 TW TW103133537A patent/TW201518283A/zh unknown
- 2010-03-31 TW TW99109929A patent/TWI464165B/zh active
- 2010-04-01 KR KR1020117026120A patent/KR101728375B1/ko active Active
- 2010-04-01 CA CA3008903A patent/CA3008903C/en active Active
- 2010-04-01 CA CA2754698A patent/CA2754698C/en active Active
- 2010-04-01 JP JP2012503704A patent/JP5612662B2/ja active Active
- 2010-04-01 CN CN202010112624.8A patent/CN111217808A/zh active Pending
- 2010-04-01 PT PT107130759T patent/PT2414325E/pt unknown
- 2010-04-01 NZ NZ617773A patent/NZ617773A/en unknown
- 2010-04-01 EP EP15171216.3A patent/EP3009434A1/en not_active Withdrawn
- 2010-04-01 PE PE2011001737A patent/PE20120617A1/es active IP Right Grant
- 2010-04-01 CN CN201080014307.7A patent/CN102438982B/zh active Active
- 2010-04-01 CA CA2925137A patent/CA2925137C/en active Active
- 2010-04-01 US US12/752,639 patent/US8497396B2/en active Active
- 2010-04-01 NZ NZ726536A patent/NZ726536A/en unknown
- 2010-04-01 NZ NZ59486410A patent/NZ594864A/en unknown
- 2010-04-01 NZ NZ708978A patent/NZ708978A/en unknown
- 2010-04-01 KR KR1020177009970A patent/KR101874557B1/ko active Active
- 2010-04-01 BR BRPI1012638A patent/BRPI1012638B8/pt active IP Right Grant
- 2010-04-01 EA EA201590979A patent/EA201590979A1/ru unknown
- 2010-04-01 AP AP2011005864A patent/AP2887A/xx active
- 2010-04-01 EP EP10713075.9A patent/EP2414325B1/en active Active
- 2010-04-01 SG SG10201404926UA patent/SG10201404926UA/en unknown
- 2010-04-01 WO PCT/US2010/029633 patent/WO2010115000A2/en not_active Ceased
- 2010-04-01 KR KR1020187018487A patent/KR20180077324A/ko not_active Ceased
- 2010-04-01 SG SG2011069937A patent/SG174585A1/en unknown
- 2010-04-01 AU AU2010232559A patent/AU2010232559B2/en active Active
- 2010-04-01 CN CN201710518109.8A patent/CN107382997B/zh active Active
- 2010-04-01 CA CA3083433A patent/CA3083433C/en active Active
- 2010-04-01 MX MX2011010397A patent/MX2011010397A/es active IP Right Grant
- 2010-04-01 EA EA201190179A patent/EA022739B1/ru unknown
- 2010-04-01 CN CN201510160505.9A patent/CN104876888B/zh active Active
- 2010-04-01 MX MX2013003678A patent/MX338731B/es unknown
- 2010-04-01 ES ES10713075.9T patent/ES2548252T3/es active Active
- 2010-04-05 UY UY32535A patent/UY32535A/es not_active Application Discontinuation
-
2011
- 2011-09-06 CO CO11114749A patent/CO6400216A2/es not_active Application Discontinuation
- 2011-09-26 CL CL2011002370A patent/CL2011002370A1/es unknown
- 2011-09-27 IL IL215399A patent/IL215399A/en active IP Right Grant
- 2011-10-11 ZA ZA2011/07430A patent/ZA201107430B/en unknown
- 2011-10-12 EC ECSP11011391 patent/ECSP11011391A/es unknown
-
2013
- 2013-06-24 US US13/925,302 patent/US8853210B2/en active Active
-
2014
- 2014-05-20 JP JP2014104007A patent/JP5986599B2/ja active Active
- 2014-09-03 US US14/476,622 patent/US9115100B2/en active Active
-
2015
- 2015-03-10 IL IL237643A patent/IL237643A/en active IP Right Grant
- 2015-03-10 IL IL237642A patent/IL237642A/en active IP Right Grant
- 2015-07-14 US US14/799,090 patent/US9428473B2/en active Active
-
2016
- 2016-01-28 JP JP2016014135A patent/JP6180561B2/ja active Active
- 2016-09-09 HK HK16110713.7A patent/HK1223912A1/en unknown
-
2017
- 2017-01-11 IL IL250068A patent/IL250068A0/en unknown
- 2017-02-27 JP JP2017034914A patent/JP6336161B2/ja active Active
- 2017-07-28 JP JP2017146329A patent/JP6491706B2/ja active Active
-
2018
- 2018-06-18 JP JP2018115527A patent/JP2018162274A/ja not_active Withdrawn
-
2020
- 2020-08-07 JP JP2020134426A patent/JP2020189861A/ja not_active Withdrawn
-
2022
- 2022-10-19 JP JP2022167506A patent/JP2023002679A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008103949A1 (en) * | 2007-02-23 | 2008-08-28 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101728375B1 (ko) | 시토크롬 ｐ４５０ 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 | |
| WO2012045007A1 (en) | Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester | |
| HK1166976B (en) | Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved | |
| HK40022057A (en) | Method and intermediates for preparing pharmaceutical agents | |
| EA016854B1 (ru) | Новый способ получения эфира 3-амино-5-фтор-4-диалкоксипентановой кислоты | |
| HK1245785B (zh) | 用於制备药物药剂的方法和中间体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20111102 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20150401 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160616 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20170112 |
|
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20170412 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20170413 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20170414 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20200330 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210324 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220323 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240319 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250317 Start annual number: 9 End annual number: 9 |